A review of paliperidone palmitate

@article{Chue2012ARO,  title={A review of paliperidone palmitate},  author={Pierre Chue and James Chue},  journal={Expert Review of Neurotherapeutics},  year={2012},  volume={12},  pages={1383 - 1397},  url={https://api.semanticscholar.org/CorpusID:36437470}}
Paliperidone long-acting injection (PLAI) has been shown in to be effective in controlling the acute symptoms of schizophrenia as well as delaying time to relapse and may represent the rational development of RLAI with greater ease of use.

59 Citations

A review of aripiprazole long-acting injection

Experience with oral aripiprazole and the current availability of the long-acting formulation suggest a potential benefit in a variety of clinical scenarios and therefore consideration as a treatment option in the treatment of schizophrenia.

Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia

Results suggest a lower risk of TF but a higher rate of some AEs after treatment with PP vs COAs, AOAs, and paliperidone/risperidone.

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone

Any clinician considering switching patients to PP1M: 1) should switch from oral risperidone toPP1M rather than from oral paliperidoneto PP3M, and 2) become proficient in paliperidsone TDM to use during switches to help during switches.

Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole

A schizoaffective disorder patient who significantly benefited from paliperidone palmitate long acting antipsychotic treatment but developed hyperprolactinemia and amenorrhea, which were resolved by adding aripiprazole.

Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia

Dose-dependent trends were observed for the effect of PP on positive, negative and uncontrolled hostility/excitement symptoms, and most (but not all) significant responses persisted to the end point.

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

Clinicians using TDM for risperidone LAI microsphere formulation need to consider steady state to be reached ≥ 6 weeks after the first injection, and pay attention to a) co-medications with inducers/inhibitors, b) severe inflammations/infections, and c) hepatic/renal impairment.

Paliperidone palmitate-induced facial angioedema: A case report

This case report presents a case report of paliperidone palmitate-induced angioedema with a relatively mild clinical presentation compared with the previously reported case, and the patient’s condition was not complicated by life-threatening anaphylaxis.

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

This comprehensive review aims to compile all the available pharmacokinetic and pharmacogenetic data regarding the three major LAI atypical antipsychotics: risperidone, paliperidone and aripiprazole.

A Comparative Pharmacokinetic Evaluation of Paliperidone Palmitate Extended-Release Injectable Suspensions: An Open Label, Randomized, Two-treatment, Two-Period, Two-Sequence, Multiple Dose, Steady State Crossover Bioequivalence Study in Patients with Schizophrenia and/or Schizoaffective Disorder

This study assessed bioequivalence and safety of paliperidone palmitate Extended-Release Extended-Release (ER) Injectable suspension (ER) injectable suspension of paliperidone for schizophrenia and Schizoaffective disorders.

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia

This review summarizes the characteristics and recent research of formulations of each long-acting injectable antipsychotic drug, including risperidone, paliperidone palmitate, and olanzapine pamoate.
...

94 References

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

PP did not demonstrate comparable efficacy to RIS-LAI, which may be attributable to the initiation dosing strategy employed, and Tolerability of both treatments was comparable to previous studies, with no new safety signals detected.

The pharmacology and formulation of paliperidone extended release

The ER formulation of paliperidone results in decreased fluctuations in plasma drug levels and allows for once-daily administration with initial tolerability that permits treatment initiation at a clinically effective dose without the need for titration, leading to potentially better adherence and improved outcome.

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Doses of once-monthly paliperidone palmitate offered the potential to improve outcomes in adults with symptomatic schizophrenia, both locally and systemically.

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia

Paliperidone extended-release has been developed as an osmotic controlled-release oral delivery system that minimizes peak-trough fluctuations in plasma concentrations, allowing once-daily administration and theoretically leading to a decreased incidence of adverse effects.

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

This article overviews the recommended dosing strategies for the treatment of schizophrenia patients using the recently FDA-approved once-monthly long-acting injectable atypical antipsychotic, paliperidone palmitate, and provides practical guidance to clinicians on how to use it in adult patients with schizophrenia.

Once-monthly paliperidone injection for the treatment of schizophrenia

Overall, paliperidone palmitate may have advantages over other currently available long-acting injections, and therefore may be a useful alternative for the treatment of schizophrenia, although further long-term trials comparing it with active treatments are warranted.

Intramuscular Paliperidone Palmitate

As maintenance therapy, intramuscular paliperidone palmitate 39–156 mg was significantly more effective than placebo in delaying the time to the first relapse of schizophrenia symptoms in adult patients, according to the results of a randomized, double-blind study.
...

Related Papers

Showing 1 through 3 of 0 Related Papers